MicroRNA expression profile of pulmonary artery smooth muscle cells and the effect of let-7d in chronic thromboembolic pulmonary hypertension

Pulmonary Circulation

Volumn 3, Issue 3, 2013, Pages 654-664

  Wang, Lei ^a,b   Guo, Li Juan ^a,b   Liu, Jie ^b   Wang, Wang ^b   Yuan, Jason X J ^c   Zhao, Lan ^d   Wang, Jun ^a,b   Wang, Chen ^b,e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e BEIJING HOSPITAL   (China)

Author keywords

Chronic thromboembolic pulmonary hypertension; Let 7d; Proliferation; Pulmonary artery smooth muscle cell

Indexed keywords

EID: 84903591380     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674310     Document Type: Article

References (36)

1. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113(16):2011-2020.
2. Moser KM, Braunwald NS. Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest 1973;64(1):29-35.
3. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993;103(3):685-692.
4. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002;45(3):173-202.
5. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8(8):443-455.
6. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S.
7. Grosshans H, Filipowicz W. Molecular biology: the expanding world of small RNAs. Nature 2008;451(7177):414-416.
8. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455(7209):58-63.
9. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009;104(10):1184-1191.
10. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011;208(3): 535-548.
11. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol 2010;299(6):L861-L871.
12. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, MacDonald RA, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010;30(4):716-723.
13. Chen Z, Nakajima T, Tanabe N, Hinohara K, Sakao S, Kasahara Y, Tatsumi K, Inoue Y, Kimura A. Susceptibility to chronic thromboembolic pulmonary hypertension may be conferred by miR-759 via its targeted interaction with polymorphic fibrinogen alpha gene. Hum Genet 2010;128 (4):443-452.
14. Jerome T, Laurie P, Louis B, Pierre C. Enjoy the silence: the story of let-7 microRNA and cancer. Curr Genomics 2007;8 (4):229-233.
15. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64(11): 3753-3756.
16. Legesse-Miller A, Elemento O, Pfau SJ, Forman JJ, Tavazoie S, Coller HA. let-7 overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts. J Biol Chem 2009;284(11):6605-6609.
17. Yu ML, Wang JF, Wang GK, You XH, Zhao XX, Jing Q, Qin YW. Vascular smooth muscle cell proliferation is influenced by let-7d microRNA and its interaction with KRAS. Circ J 2011;75(3):703-709.
18. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, et al. (the Gene Ontology Consortium). Gene ontology: tool for the unification of biology. Nat Genet 2000;25(1):25-29.
19. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res 2004;32(Suppl 1):D277-D280.
20. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. A systems biology approach for pathway level analysis. Genome Res 2007;17(10):1537-1545.
21. Shalgi R, Lieber D, Oren M, Pilpel Y. Global and local architecture of the mammalian microRNA-transcription factor regulatory network. PLoS Comput Biol 2007;3(7):e131.
22. Joung JG, Hwang KB, Nam JW, Kim SJ, Zhang BT. Discovery of microRNA-mRNA modules via population-based probabilistic learning. Bioinformatics 2007;23(9):1141-1147.
23. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, et al. The let-7 micro-RNA represses cell proliferation pathways in human cells. Cancer Res 2007;67(16):7713-7722.
24. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345(20):1465-1472.
25. Manecke GR Jr., Wilson WC, Auger WR, Jamieson SW. Chronic thromboembolic pulmonary hypertension and pulmonary thromboendarterectomy. Semin Cardiothorac Vasc Anesth 2005;9(3):189-204.
26. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004;68(2):75-103.
27. Jamaluddin MS, Weakley SM, Zhang L, Kougias P, Lin PH, Yao Q, Chen C. miRNAs: roles and clinical applications in vascular disease. Expert Rev Mol Diagn 2011;11(1):79-89.
28. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118(7):2372-2379.
29. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2007;27(5):1072-1078.
30. Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF, Ishizaki T. p53 gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol 2011;300(5):L753-L761.
31. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009;35(6):856-867.
32. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000;408(6808):86-89.
33. O’Hara AJ, Wang L, Dezube BJ, Harrington WJ Jr., Damania B, Dittmer DP. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood 2009;113(23):5938-5941.
34. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008;105(10):3903-3908.
35. He X, Duan C, Chen J, Ou-Yang X, Zhang Z, Li C, Peng H. Let-7a elevates p21WAF1 levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells. FEBS Lett 2009;583(21):3501-3507.
36. Ricarte-Filho JC, Fuziwara CS, Yamashita AS, Rezende E, da-Silva MJ, Kimura ET. Effects of let-7 microRNA on cell growth and differentiation of papillary thyroid cancer. Transl Oncol 2009;2(4):236-241